Cagrilintide CGL
Amylin analogue
Long-acting synthetic analogue of amylin, a satiety-signalling hormone, studied alone and alongside GLP-1 receptor agonists.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Amylin analogue
- Category
- Metabolic & Incretin
- Type
- Single compound
- Abbreviation
- CGL
- Development and regulatory status
- Investigational amylin analogue; not approved as a standalone drug
What researchers study
Cagrilintide is a long-acting synthetic analogue of amylin, a hormone released with insulin that signals satiety. It acts on amylin and calcitonin receptors and is studied alone and alongside GLP-1 receptor agonists.
Research areas
- Amylin and calcitonin receptor signalling studies
- Satiety and food-intake pathways in models
- Combination studies with GLP-1 receptor agonists
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 2 trial
In 706 adults without diabetes, mean weight change at 26 weeks across cagrilintide groups was -6.0% to -10.8% versus -3.0% with placebo
- phase 2 trial
In the same trial, the highest cagrilintide dose group differed from the liraglutide comparator (-9.0%) by -1.8 percentage points (P=0.03)
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- SemaglutideGLP-1 agonist studied together with cagrilintide in the CagriSema programme
- CagriSemafixed combination of cagrilintide and semaglutide
- Retatrutidetriple agonist with incretin and glucagon pathways complementary to amylin signalling
- LiraglutideGLP-1 agonist used as comparator in the phase 2 cagrilintide trial
